Catalent announces biologics development

A total of £120 million ($160 million) is expected to be spent on completing the construction of the facility and equipping it with the most advanced modalities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced technologies.

In addition to employing more than 400 people, the new facility will support public and private organizations seeking to develop and manufacture biotherapeutics.

“This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centered around Oxford, with its world-class talent, and will result in a facility that provides opportunities to transform innovation into real treatments for patients across the UK, Europe and beyond,” said Mike Riley, president of Catalent Biotherapeutics.